Therapy-naive patients with mutated B-CLL (M-CLL) have a tendency to respond less to ibrutinib treatment than patients with unmutated V-gene CLL (U-CLL) [84]. Here, PPIB is linked to B-cell chronic lymphocytic leukemia.